1 Active trachoma among children aged 1-9 years in Ethiopia:

2 A meta-analysis from 2019 to 2024

Kibruyisfaw Weldeab Abore¹, Melat Tesfaye Asebot², Gifty Birhanemeskel Kebede¹, Robel
Tibebu Khasay¹, Asonya Abera Akuma³, Mahlet Minwuyelet Dagne⁴, Tewobesta Fesseha
Tesfaye⁵, Mahlet Tesfaye Abebe⁶, Estifanos Bekele Fole⁶

6

⁷ ¹Department of Ophthalmology, St. Paul's Hospital Millennium Medical College, Addis Ababa,

8 Ethiopia

- 9 ²Bloomberg School of Public Health, John Hopkins University, USA
- ³College of medicine and health sciences, Arbaminch University, Arbaminch, Ethiopia
- ⁴St. Peter's specialized hospital, Addis Ababa, Ethiopia
- ⁵Ministry of health Ethiopia, Addis Ababa, Ethiopia
- 13 ⁶Department of Medicine, Yirgalem Hospital Medical College, Yirgalem, Ethiopia

14

- 15 Corresponding author:
- 16 Kibruyisaw Weldeab Abore (Kibruyisfaww@gmail.com)

17

1 Abstract

Background: Trachoma is a leading infectious cause of blindness and of significant public
health concern targeted for elimination. This study aimed to systematically summarize the
magnitude of active trachoma among children aged 1-9 in Ethiopia from 2019-2024

5 **Methods:** Database searches were conducted on Google Scholar, SCOPUS, PubMed, EMBASE, 6 and AJOL for studies published between January 2019 to 31-March-2024 and with restriction to 7 articles published only in English. Data extraction was done using a pre-prepared Excel sheet. 8 STATA version 17 was used to perform the analysis. Heterogeneity between studies was assessed 9 using I² statistics and Cochrane Q. Qualitative synthesis was done to summarize the studies and 10 random effect model was used to estimate the Pooled magnitude of active trachoma with a 11 corresponding 95% confidence interval.

Result: A total of 17 studies with 19793 subjects were included in the meta-analysis. The pooled magnitude of active trachoma among children aged 1-9 years was found to be 18.4% (95% CI: 13.88, 22.91). We found a statistically significant heterogeneity between studies. Among the regions, Southwest region was found to have the highest magnitude (44.1%) (95%CI: 41.8%, 46.4%) and Dire Dawa was found to have the lowest (4.3%) (95%CI: 2.9%, 5.7%).

Conclusion: The magnitude of active trachoma is higher than the WHO target for elimination.
There was significant interregional difference in magnitude of active trachoma. Strengthening
SAFE strategy and health education and promotion is recommended.

20

1 Introduction

Trachoma is an infectious ocular disease caused by the bacteria Chlamydia trachomatis and it is the leading infectious cause of blindness worldwide [1]. Active trachoma is defined by the presence of trachomatous inflammation–follicular (TF) and/or trachomatous inflammation– intense (TI) in at least one eye [2]. Trachoma primarily affects impoverished communities within low-income and middle-income nations. Trachoma is endemic in 57 countries globally, and it is responsible for the blindness and visual impairment of nearly 2 million people [3-5].

8 Africa bears the largest burden of trachoma globally with prevalence of TF ≥30% at most recent
9 surveys [6]. Trachoma is the second most common cause of blindness in Ethiopia and still
10 constitutes a disease of public health concern [7].

11 Trachoma disproportionately affects disadvantaged and marginalized groups within communities 12 [8]. In endemic areas, active cases of the disease are common among the preschool children, with 13 varying magnitude [9]. Children exhibiting the active stages of trachoma also serves as the 14 reservoir for the transmission of infection [10]. Trachoma is managed through an endorsed, 15 comprehensive strategy comprising of surgical treatment for trichiasis, antibiotic therapy, facial 16 hygiene, and environmental improvement, collectively known as the SAFE strategy [11].

A previous meta-analysis done in 2019 had shown that the magnitude of active trachoma among children to be 26.9% [8]. This magnitude is expected to rise due to the wars and conflicts in Ethiopia over the past 5 years and its associated internal displacement. Furthermore, public health efforts would be affected which would negatively affect the progress towards trachoma elimination [12]. In addition, multiple studies were carried out in various regions of Ethiopia over the last five years and significant discrepancies in magnitude were seen. This concern highlights the need to

combine the findings from these studies to establish evidence-based suggestions. Thus, this study
 aimed to systematically summarize and pool the magnitude of active trachoma among children
 aged 1-9 years in Ethiopia from 2019-2024.

4 Method and materials

5 Study design

6 This systematic review and meta-analysis was prospectively registered on PROSPERO
7 (Registration number: CRD42024514026).

8 Search strategy and sources

9 Two reviewers independently conducted searches on Google Scholar, SCOPUS, PubMed, 10 EMBASE, and AJOL. The search was made using the terms active trachoma, children, and 11 Ethiopia using Boolean operators 'AND' and 'OR'. The search was restricted to articles published 12 between January 2019 to March 31 2024 and to those published in English. Literatures were 13 rechecked after completion of the study. Preferred Reporting Items for Systematic reviews and 14 Meta-Analyses (PRISMA) guideline was used to report the study selection steps.

15 Eligibility criteria

The inclusion criteria for the study was studies that were conducted between 2019-2024, that are published in English, and that assessed the magnitude of active trachoma among children 1-9 years in Ethiopia. Studies that did not report on the outcome of interest, studies done before 2019, those conducted outside of Ethiopia, studies which are not published in English language, studies which are not peer reviewed, and studies without retrievable full article were excluded from the study.

1 Quality appraisal

The Newcastle-Ottawa scale (NOS) adapted for cross-sectional studies was used to assess the quality of studies included in the review [13]. It assess selection, comparability, and outcome domains of studies with 5, 2, and 3 stars maximum given for selection, comparability, and outcome domains respectively. Two reviewers independently assessed the quality of studies. Studies with a score of less than 7 were labeled as poor and those with ≥7 were assessed as good quality studies. A third reviewer settled disagreement in scoring between the two reviewers through discussions.

8 Data extraction

9 Identified literature were imported to Covidence and examined against the eligibility criteria by 10 two reviewers. A third reviewer served as a mediator when there was disagreement. Using a pre-11 prepared excel sheet, two reviewers with the help of a third reviewer, extracted data. We collected 12 data regarding the name of the primary author, publication year, year of study conduct, region of 13 the study, study design, sample size, and active trachoma magnitude with 95% confidence interval.

14 Data processing and analysis

The extracted data were exported to STATA v.17 for analysis. Cochran's Q test and I² statistics were used to assess heterogeneity among studies. Using a random effects model, we computed the pooled magnitude of active trachoma among children and presented it using a forest plot. A Subgroup analysis was conducted based on region and Meta-regression was done using sample size and year of publication as covariates. A leave one out sensitivity analysis was computed. We assessed publication bias using Funnel plot and Eggers test.

1 Ethical statement

2 N/A

3

4 **Results**

5 Study screening and selection

6 The search strategy identified a total of 570 studies. Subsequently, 98 duplicate studies were 7 removed. After reviewing title and abstract, 422 studies were removed. Full article screening was 8 done on 50 articles, and 9 studies that did not report on magnitude of trachoma, 21 studies based 9 on year of study, 1 study done on adult subjects, and 2 studies without clear study period were 10 excluded. Finally, 17 studies were found to be eligible for the meta-analysis. (**Fig 1**)

Fig 1. PRISMA study selection flow for systematic review and meta-analysis of active trachoma among children aged 1-9 years in Ethiopia: A meta-analysis from 2019 to 2024

13 Study characteristics

Of the studies, 5 were done in Amhara region [14-18], 3 in Oromia region [19-21], 2 from Southen
region [22, 23], 3 in Gambella [24-26], 1 from South West Ethiopia region[27], 1 in Benishangul
Gumuz [28], 1 in Sidama [29], and 1 in Diredawa city [30]. Based on NOS assessment of quality,
all included studies had good quality (a score ≥7). In terms of the number of study participants,
the largest sample size was 5489 [25] and smallest was 178 [20]. All included studies were crosssectional study design. (Table 1)

1 Table 1. Characteristics of studies included for systematic review and meta-analysis on active

2 trachoma among children aged 1-9 years in Ethiopia from 2019-2024

Authors	Year of publication	Region	Study design	SS	NOS score
Asmare Z. et al[16]	2023	Amhara	Cross-sectional	540	8
Altaseb et al [15]	2024	Amhara	Cross-sectional	616	9
Genet et al [14]	2022	Amhara	Cross-sectional	704	9
Melkie et al[17]	2020	Amhara	Cross-sectional	678	9
Shimelash et al[18]	2022	Amhara	Cross-sectional	394	9
Mekonnen et al[20]	2022	Oromia	Cross-sectional	178	7
Shafi et al[21]	2023	Oromia	Cross-sectional	526	7
Tuke et al[19]	2023	Oromia	Cross-sectional	538	8
Mengiste et al[28]	2022	Benishangul	Cross-sectional	4590	7
Mohamed et al[30]	2019	Diredawa	Cross-sectional	823	8
Delelegn et al[29]	2021	Sidama	Cross-sectional	701	7
Getachew et al[27]	2023	South West Ethiopia	Cross-sectional	1292	10
Alemayehu et al[25]	2023	Gambella	Cross-sectional	5489	7
Senebete et al [24]	2024	Gambella	Cross-sectional	722	8
Yitayeh et al [26]	2021	Gambella	Cross-sectional	610	8
Abdilwohab et al[22]	2020	Southern region	Cross-sectional	831	9
Shemsu et al[23]	2021	Southern region	Cross-sectional	561	8

1 Meta-analysis of Active trachoma among children 1-9 years of age in

2 Ethiopia

We included 17 studies for the meta-analysis with a total sample size of 19793. Due to the 3 4 statistically significant heterogeneity among studies, we used random effect model to estimate the pooled magnitude of active trachoma. The magnitude of active trachoma among children was 5 found to be 18.4% (95% CI: 13.88, 22.91) (Fig 2). Meta-regression done using sample size and 6 year of study found that both are not statistically significant sources of heterogeneity (Table 2). 7 8 Subgroup analysis based on the region of the study was conducted and between studies 9 heterogeneity persisted. Southwest region was found to have the highest magnitude of active trachoma (44.1%) while Dire Dawa City was found to have the lowest magnitude (4.3%).(Table 10 3). 11

Fig 2. Pooled magnitude of active trachoma among children aged 1-9 years in Ethiopia from 2019-2024

14 Table 2. Meta-regression analysis of factors affecting between-study heterogeneity.

Source	Coefficient	Std. error	p-value
Year of publication	2.81268	1.87961	0.135
Sample size	-0.02064	0.00180	0.253

15

1 Table 3. Subgroup analysis based on region for active trachoma among children aged 1-9

2 years in Ethiopia from 2019-2024

Region	Pooled magnitude	95% CI	Heterogeneity (I ²)	
Amhara	14%	3.57, 24.44	98.87%	
Oromia	24.11%	18.71, 29.5	76.59%	
Southern region	23.51%	12.14, 34.88	96.13%	
Sidama	17.5%	14.15, 20.85	-	
Gambella	16.82%	11.68, 21.96	91.43%	
Southwest region	44.1%	41.8, 46.4	-	
Dire Dawa	4.3%	2.9, 5.7	-	
Benishangul Gumuz	8.04%	7.24, 8.83	-	

3

4 Sensitivity analysis

A leave-one-out sensitivity analysis was conducted to assess the effect of one study on the overall
effect size estimate. We found that no single study had a significant effect on the overall effect
size estimate. (Table 4)

8

9

1 Table 4. A leave one out sensitivity analysis for studies on active trachoma among children

2 aged 1-9 years in Ethiopia from 2019-2024

Omitted study	Effect size	[95% conf.	[95% conf. interval]	
		Upper	lower	
Asmare ZA, 2023	17.348	12.873	21.824	0.000
Altaseb T., 2024	18.875	14.118	23.632	0.000
Genet A., 2022	19.192	14.418	23.967	0.000
Melkie G, 2020	19.043	14.269	23.817	0.000
Shimelash A., 2022	18.933	14.207	23.660	0.000
Mengistu B., 2022	19.084	13.824	24.343	0.000
Mohamed H., 2019	19.303	14.556	24.051	0.000
Alemayehu A., 2023	18.781	13.338	24.224	0.000
Senbete L, 2024	18.515	13.830	23.199	0.000
Yitayeh B, 2021	18.197	13.536	22.857	0.000
Mekonnen J, 2022	18.195	13.553	22.838	0.000
Shafi Abdurahman O, 2023	18.241	13.577	22.905	0.000
Tuke D., 2023	17.732	13.154	22.309	0.000
Delelegn D., 2021	18.454	13.760	23.148	0.000
Getachew D., 2023	16.623	13.369	19.877	0.000
Abdilwohab G., 2020	18.438	13.712	23.163	0.000
Shemsu K, 2021	17.712	13.153	22.271	0.000
Theta	18.396	13.884	22.908	0.000

3

4 **Publication bias**

5 We assessed publication bias using a funnel plot and Egger's test. The funnel plot was found to be 6 slightly asymmetric to the right (**Fig 3**) and Egger's test showed a statistically significant

publication bias (p-value=0.0112). Subsequently, trim and fill analysis was done with no change
in the estimated effect size. The result of Egger's test was assumed to be originating from the
statistically significant heterogeneity.

Fig 3. Funnel plot assessing publication bias for active trachoma among children aged 1-9
years in Ethiopia from 2019-2024

6 **Discussion**

The study showed that there is a high prevalence of active trachoma among children 1-9 years in 7 Ethiopia, with significant variation in prevalence among different regions of the country. The 8 9 pooled variance is 18.4% which is markedly higher than the World Health Organization's (WHO) target of trachoma elimination of less than 5% active trachoma [4]. The finding is comparable with 10 a previous report by Gebrie et al in 2019 which showed a pooled prevalence of 26.9% and similar 11 12 disparities among regions. [8] Although their study reported a similar pattern and trend, the study period was limited to the year 2019. Our study extended from 2019-2024 which makes it relevant 13 in capturing effects of recent occurrences such as the ongoing war and conflicts in the country over 14 the past five years. 15

Previous studies have highlighted the significant consequence of war and displacement in hindering disease control by disrupting healthcare infrastructure, reducing access to clean water and sanitation, and spreading infectious diseases because of migration [5, 12]. Despite the current ongoing war and displacement in the country, the pooled prevalence of our study is lower than the one reported 5 years ago (26.9% Vs 18.4%). One possible reason could be that data from Tigray and Afar, regions which are heavily affected by the war, are not included in our study due to a lack of data from those regions. Therefore, the reported prevalence might underestimate the true

1 prevalence.

Several other factors may contribute to this high prevalence rate that persisted in the country 2 despite implementing control measures to reduce the burden. The low socioeconomic status of the 3 country is the major one which results in a lack of access to clean water and inadequate sanitation. 4 According to UNICEF and WHO's report, 48% of the population lacks access to clean water and 5 functional latrines, which significantly impacts hygiene practices and increases the risk of 6 trachoma transmission [31]. Lack of hygiene is a significant factor in the spread of infection. 7 Global studies have indicated that countries with poor sanitation and water supply have higher 8 9 trachoma prevalence, underscoring the need for comprehensive public health interventions [32-34]. A study by Garn et al. demonstrated the inverse relation between adequate water and sanitation 10 facilities and trachoma prevalence [2]. Poverty is also inversely related to education and health 11 care access which are essential factors to the successful implementation of control measures. 12 Trachoma was indicated as an indicator of poverty [35]. 13

Cultural practices are another factor contributing to the high prevalence of trachoma. Some practices such as using clothes to clean eyes, inadequate showers, and facial cleanliness further been reported to increase the risk of trachoma transmission [36]. War and conflict on top of this lays a fertile ground for the increase in transmission.

To reduce Trachoma prevalence the WHO recommended SAFE (Surgery for trichiasis, Antibiotic to clear infection, Facial cleanliness, and Environmental improvement) strategy should be strengthened [6, 37]. Building infrastructures for Water, Sanitation, and Hygiene (WASH) is also critical to hinder the transmission of trachoma [3, 6]. Special emphasis should be given to areas with higher prevalence. Empowering the public by raising awareness about the severity of the prevalence and the resulting blindness as well as the hygiene techniques could ease the burden and

should be widely implemented. A due focus also should be given to expanding and equipping
healthcare facilities with trained staff and resources to combat trachoma. Lastly, a robust
surveillance system to monitor the prevalence and impact of intervention should be in play to
monitor and evaluate the implementations.

Eleven countries, including 3 from Africa (The Gambia, Ghana, Morocco), have eliminated
trachoma in 2022 [1]. This could indicate public health interventions such as the sustained SAFE
strategy implementation can lead to the elimination of trachoma. These countries serve as a great
example and those strategies should be tailored to the country's status and implemented to achieve
the elimination target.

10 Limitation

Despite its strength in shedding light on the prevalence of trachoma, our study has some limitations.
The first is that the included studies are cross-sectional studies hence limiting causal inferences.
Second, the exclusion of conflict-affected regions like Tigray and Afar due to a lack of recent data
may result in an underestimation of the true prevalence of active trachoma in Ethiopia. This
warrants cautious interpretation of the result.

16 Conclusion

Although it has decreased from the previously reported magnitude, active trachoma is still higher than the WHO target for elimination and is a disease of public health concern. We recommend strengthening the SAFE strategy to better tackle the problem as well as working with relevant stakeholders about health education and health promotion. Future research should focus on longitudinal analysis to better understand the transmission of trachoma and associated sociodemographic factors in different regions of the country. The long-term impact of the ongoing

intervention should also be assessed in future studies. These studies will help tailor public health
interventions based on the specific findings in the regions. Additionally, research comparing
trachoma control efforts in Ethiopia with those in other high-prevalence countries can provide
valuable insights into effective strategies and potential areas for improvement.

5

6 References

7

Renneker KK, Abdala M, Addy J, Al-Khatib T, Amer K, Badiane MD, et al. Global progress
 toward the elimination of active trachoma: an analysis of 38 countries. The Lancet Global Health.
 2022;10(4):e491-e500.

Garn JV, Boisson S, Willis R, Bakhtiari A, Al-Khatib T, Amer K, et al. Sanitation and water supply
 coverage thresholds associated with active trachoma: modeling cross-sectional data from 13 countries.
 PLoS neglected tropical diseases. 2018;12(1):e0006110.

14 3. Dye C, Mertens T, Hirnschall G, Mpanju-Shumbusho W, Newman RD, Raviglione MC, et al.

15 WHO and the future of disease control programmes. Lancet. 2013;381(9864):413-8.

16 4. Organization WH. Global WHO alliance for the elimination of blinding trachoma by 2020. Weekly

17 Epidemiological Record= Relevé épidémiologique hebdomadaire. 2012;87(17):161-8.

18 5. Marie. Deadly comrades: war and infectious disease. THE LANCET. 2002;360.

19 6. Report of the 21th meeting of the WHO alliance for the global elimination of trachoma by 2020

20 [Internet]. Available from: https://www.who.int/publications/i/item/who-cds-ntd-pct-2019.02 Report of the

21 21th meeting of the WHO alliance for the global elimination of trachoma by 2020.

22 7. Miecha H, Dejene M, Adugna D, Kebede A, Yadeta D, Alemayehu A, et al. Prevalence of

23 Trachoma after Implementation of Trachoma Elimination Interventions in Oromia Regional State, Ethiopia:

Results of Impact Surveys in 131 Evaluation Units Covering 139 Districts. Ophthalmic Epidemiology.
 2023;30(6):647-54.

Gebrie A, Alebel A, Zegeye A, Tesfaye B, Wagnew F. Prevalence and associated factors of active
 trachoma among children in Ethiopia: a systematic review and meta-analysis. BMC Infectious Diseases.
 2019;19(1):1073.

Ferede AT, Dadi AF, Tariku A, Adane AA. Prevalence and determinants of active trachoma among
 preschool-aged children in Dembia District, Northwest Ethiopia. Infectious Diseases of Poverty.
 2017;6(1):128.

9 10. Australia CDN. CDNA National Guidelines for the Public Health Management of Trachoma. Do
10 Health, Editor. 2014.

11 11. Tian L, Wang NL. Trachoma control: the SAFE strategy. Int J Ophthalmol. 2018;11(12):1887-8.

Marou V, Vardavas CI, Aslanoglou K, Nikitara K, Plyta Z, Leonardi-Bee J, et al. The impact of
conflict on infectious disease: a systematic literature review. Conflict and Health. 2024;18(1):27.

Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, et al. Panethnic
differences in blood pressure in Europe: a systematic review and meta-analysis. PloS one.
2016;11(1):e0147601.

17 14. Genet A, Dagnew Z, Melkie G, Keleb A, Motbainor A, Mebrat A, et al. Prevalence of active
trachoma and its associated factors among 1–9 years of age children from model and non-model kebeles in
Dangila district, northwest Ethiopia. Plos one. 2022;17(6):e0268441.

20 15. Altaseb T, Lingerew M, Adane M. Prevalence of trachomatous inflammation-follicular and
21 associated factors among children aged 1-9 years in northeastern Ethiopia. BMC pediatrics.
22 2024;24(1):128.

Asmare ZA, Seifu BL, Mare KU, Asgedom YS, Kase BF, Shibeshi AH, et al. Prevalence and
associated factors of active trachoma among 1–9 years of age children in Andabet district, northwest
Ethiopia, 2023: A multi-level mixed-effect analysis. PLOS Neglected Tropical Diseases.
2023;17(8):e0011573.

1 17. Melkie G, Azage M, Gedamu G. Prevalence and associated factors of active trachoma among 2 children aged 1-9 years old in mass drug administration graduated and non-graduated districts in Northwest 3 Amhara region, Ethiopia: A comparative cross-sectional study. PLoS One. 2020;15(12):e0243863. 4 18. Shimelash A, Alemayehu M, Dagne H, Mihiretie G, Lamore Y, Tegegne E, et al. Prevalence of 5 active trachoma and associated factors among school age children in Debre Tabor Town, Northwest 6 Ethiopia, 2019: a community based cross-sectional study. Italian Journal of Pediatrics. 2022;48(1):61. 7 19. Tuke D, Etu E, Shalemo E. Active trachoma prevalence and related variables among children in a 8 pastoralist community in southern Ethiopia in 2021: a community-based cross-sectional study. The 9 American Journal of Tropical Medicine and Hygiene. 2023;108(2):252. 20. Mekonnen J, Kassim J, Ahmed M, Gebeyehu N. Prevalence of active trachoma and associated 10 factors among children 1-9 years old at Arsi Negele Town, West Arsi Zone, Oromia Regional State, 11 12 Southern Ethiopia. Plos one. 2022;17(10):e0273808. 13 21. Shafi Abdurahman O, Last A, Macleod D, Habtamu E, Versteeg B, Dumessa G, et al. Trachoma risk factors in Oromia Region, Ethiopia. PLoS Neglected Tropical Diseases. 2023;17(11):e0011679. 14 22. 15 Glagn Abdilwohab M, Hailemariam Abebo Z. High prevalence of clinically active trachoma and 16 its associated risk factors among preschool-aged children in arba Minch health and demographic 17 surveillance site, southern Ethiopia. Clinical Ophthalmology. 2020:3709-18. 23. 18 Kedir S, Lemnuro K, Yesse M, Abdella B, Muze M, Mustefa A, et al. Prevalence and Factors 19 Associated with Active Trachoma among Children 1-9 years of Age in the Catchment Population of Tora Primary Hospital, Silte zone, Southern Ethiopia, 2020. The Open Ophthalmology Journal. 2021;15(1). 20 21 24. Senbete L, Adhena G. Magnitude of Active Trachoma Among Host and Refugee Children in Gambella Regional State, Ethiopia. Clinical Ophthalmology. 2024:777-89. 22 23 25. Alemayehu A, Mekonen A, Mengistu B, Mihret A, Asmare A, Bakhtiari A, et al. Prevalence of 24 Trachoma After Three Rounds of Antibiotic Mass Drug Administration in 13 Woredas of Gambella Region,

25 Ethiopia. Ophthalmic epidemiology. 2023:1-9.

Belsti Y, Fekadu SA, Assem AS. Active trachoma prevalence and its associated factors among
 children aged 1-9 years in rural residents of Lare District, Southwest Ethiopia. International Journal of
 Ophthalmology. 2021;14(11):1756.

4 27. Getachew D, Woldekidan F, Ayele G, Bekele Y, Sleshi S, Tekalgn E, et al. High prevalence of
5 active trachoma and associated factors among school-aged children in Southwest Ethiopia. PLOS Neglected
6 Tropical Diseases. 2023;17(12):e0011846.

Mengistu B, Wirtu F, Alemayehu A, Alene S, Asmare A, Backers S, et al. Prevalence of trachoma
in Benishangul Gumuz Region, Ethiopia, after implementation of the SAFE strategy: Results of four
population-based surveys. Ophthalmic epidemiology. 2022:1-9.

Delelegn D, Tolcha A, Beyene H, Tsegaye B. Status of active trachoma infection among school
children who live in villages of open field defecation: a comparative cross-sectional study. BMC public
health. 2021;21:1-10.

30. Mohamed H, Weldegebreal F, Mohammed J, Gemechu A. Trachoma and Associated Factors
among School Age Children 4-9 Years in Dire Dawa Administration, Eastern Ethiopia. East African Journal
of Health and Biomedical Sciences. 2019;3(2):45-54.

31. Organization WH. 2017 annual report WHO/UNICEF joint monitoring programme for water
supply, sanitation and hygiene. 2017 annual report WHO/UNICEF joint monitoring programme for water
supply, sanitation and hygiene2017. p. 20-.

32. Satasuk Joy Bhosai RLB, Bruce D. Gaynor, Thomas M. Lietman. Trachoma: An Update on
Prevention, Diagnosis, and Treatment. Curr Opin Ophthalmol. 2012.

21 33. Patel. BAMZBC. Trachoma. National Institutes of Health. 2024.

22 34. Yitayeh Belsti SAF, Abel Sinshaw Assem. Active trachoma prevalence and its associated factors


among children aged 1-9 years in rural residents of Lare District, Southwest Ethiopia. Int J Ophthalmol.

24 2021;14.

- 1 35. Esmael Habtamu TW, Sintayehu Aweke, Zerihun Tadesse, Mulat Zerihun ZZ, Kelly Callahan,
- Paul M. Emerson, et al. Trachoma and Relative Poverty: A Case- Control Study. PLOS Neglected Tropical
 Diseases. 2015.
- 4 36. Marx R. Social factors and trachoma: a review of the literature. Soc Sci Med. 1989;29(1):23-34.
- 5 37. Organization WH. Trachoma 2019 [Available from: <u>https://www.who.int/news-room/fact-</u>
 6 <u>sheets/detail/trachoma</u>.
- 7

8 Supporting information

- 9 S1. PRISMA 2020 checklist
- 10 S2. Data set



*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).

**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71


figure

Study		Effect Size with 95% Cl	Weight (%)
Asmare ZA, 2023		35.37 [31.32, 39.41]	5.78
Altaseb T., 2024	-	10.90 [8.40, 13.40]	5.95
Genet A., 2022		6.00 [4.20, 7.80]	6.00
Melkie G, 2020		8.30 [6.15, 10.45]	5.98
Shimelash A., 2022		9.90 [7.00, 12.80]	5.91
Mengistu B., 2022		8.04 [7.24, 8.83]	6.05
Mohamed H., 2019		4.30 [2.90, 5.70]	6.02
Alemayehu A., 2023		12.86 [11.96, 13.76]	6.04
Senbete L, 2024		16.50 [12.55, 20.45]	5.79
Yitayeh B, 2021	-	21.60 [18.45, 24.75]	5.88
Mekonnen J, 2022		21.91 [15.59, 28.23]	5.41
Shafi Abdurahman O, 2023		20.91 [17.34, 24.48]	5.84
Tuke D., 2023	-	29.20 [25.10, 33.30]	5.77
Delelegn D., 2021		17.50 [14.15, 20.85]	5.86
Getachew D., 2023		44.10 [41.80, 46.40]	5.96
Abdilwohab G., 2020	-	17.80 [15.30, 20.30]	5.95
Shemsu K, 2021		29.40 [25.69, 33.11]	5.82
Overall	-	18.40 [13.88, 22.91]	
Heterogeneity: $\tau^2 = 87.49$, $I^2 = 98.86\%$, $H^2 = 87.78$			
Test of $\theta_i = \theta_j$: Q(16) = 1404.49, p = 0.00			
Test of θ = 0: z = 7.99, p = 0.00			
	0 5	50	

Random-effects DerSimonian-Laird model

figure

Funnel plot



figure